A greater intake of bioavailable carotenoids, particularly lutein/zeaxanthin and beta-carotene, has been linked to a reduced risk of advanced age-related macular degeneration (AMD) based on two prospective cohort studies. The research appears in JAMA Ophthalmology.
Significant disparities in care and outcomes exist for children with retinoblastoma, according to a study published in JAMA Pediatrics.
The New Drug Application (NDA) for Dextenza (sustained release dexamethasone; Ocular Therapeutix) 0.4mg Intracanalicular Depot has been submitted to the FDA for the treatment of ocular pain following ophthalmic surgery.
Featured courses from mycme
Among the many issues clinicians face today, staying current with advances in medicine is becoming ...
This module reviews all topics on the NCCPA examination blueprint relating to Pulmonology, Ophthalmology, and ...
This webcast will discuss the pathophysiology and diagnostic criteria of VMA/VMT and treatment options for ...
- The Vitamin D Debate: Conundrums and Complexities, Part 2
- Nasal Allergy Spray Currently Unavailable
- A Rare Case of Ketoacidosis in a Non-Diabetic Patient: What's the Cause?
- Drug Used to Reduce Mortality After MI Discontinued, Generic in Shortage
- CDC Warns of Drug-Resistant 'Superbug' in Multiple U.S. Cities
- Probiotic Intervention May Reduce CDI Rates in Antibiotic Recipients
- Renal Status Not a Factor for Tedizolid, Linezolid Efficacy in ABSSSI
- Inappropriate Empirical Antimicrobial Tx May Lengthen Hospitalization
- Are C. diff Cure Rates Better With High Dose Vancomycin?
- Opioid Use Ups Hospitalization Risk for Serious Infection in Older Adults